Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Shares of Novo Nordisk fell around 3% on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top ...

Novo Nordisk's top investor moved to take control of the drugmaker's board on Tuesday, vowing a sharper focus on the key U.S.

The company behind weight-loss jab Wegovy and diabetes drug Ozempic will have a boardroom clear-out, with seven board members ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk is striving to maintain Medicaid reimbursement for its obesity drug, Wegovy, as several U.S. states face ...

Novo Nordisk's top shareholder aims to rejuvenate its board, focusing on U.S. market growth for Wegovy. France heightens bird ...

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...